<?xml version="1.0" encoding="utf-8"?>
	<collection>
		
	
		<source>SourceData</source>
		
	
		<date>2019-04-19</date>
		
	
		<key>sourcedata.key</key>
		
	
		<document>
			
		
			<id>5283606 Figure_1-A</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 1-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>The syntheses of the ligands PR-924, 9, 14, 16, 17 and 18 have been described previously (de Bruin et al, 2014). All ligands share the peptide scaffold shown in the upper left corner with P1, P2 and P3 side chains and an N-cap; they are equipped with a l-Ala (stereochemistry (S)) or d-Ala (stereochemistry (R)) residue at P3 (red) and either an N-acylmorpholine or a 3-methyl-1H-indene group (green). Furthermore, compounds differ in their P2 residue (either methoxytyrosine or tryptophane; blue). Inhibitor 9, also termed LU-015i, is endowed with an exceptional cyclohexyl residue (gray), which is associated with increased selectivity for human β5i.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:differ</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="6" offset="425"/>
					
				
					<text>differ</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:Ala</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="3" offset="255"/>
					
				
					<text>Ala</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:Ala</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="3" offset="286"/>
					
				
					<text>Ala</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_2-A</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 2-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>A. Inhibition of human β5c and β5i by ONX 0914 and PR-924. IC50 values are deduced from the fitted data.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_3-E</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 3-E</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_3-E</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>E. Serial dilutions of yeast cells were spotted on YPD plates and grown for 2 days either at 30 °C or 37 °C. Mutant yeasts are significantly retarded in growth and show increased temperature sensitivity.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_3-F</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 3-F</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_3-F</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>F. Surface illustration of the yCP. The β5 and β6 subunits are depicted in dark gray, with the residue ranges that correspond to mammalian β5 and β6 subunits in the chimeric proteasomes highlighted in gold and blue, respectively. The β5' and β6' subunits of the second β-ring are hidden on the back of 20S proteasome.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_4-A</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 4-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>A. Superposition of the β5i/β6 active sites of genuine mouse iCP and the hβ5i/hβ6 human/yeast chimera illustrates that Met45 adopts the same 'open' conformation in both structures. Amino acid side chains important for substrate binding are depicted as sticks. The catalytic Thr1 is colored in black. Met31, the single amino acid difference between mouse and human β5i active sites, is highlighted in green.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_4-B</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 4-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>B. Superposition of the genuine mouse and the human chimeric β5c/β6 active sites according to panel A proves the proper orientation of Met45 in the 'closed' conformation.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_4-C</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 4-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>C. Superposition of the β5c/β6 and β5i/β6 active sites of the natural mouse cCP and iCP according to panel A. Note the distinct conformations of Met45 (Huber et al, 2012).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_4-D</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 4-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>D. Superposition of the hβ5c/hβ6 and the hβ5i/hβ6 chimeric proteasomes confirm the distinct positions of Met45 analogously to the natural mouse subunits shown in panel C.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_5-A</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 5-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>A. Complex structures of the human β5c/β6 (left) and β5i/β6 (right) chimeric proteasomes with PR-924. The ligand binds in a linear (l) manner to the β5c/β6 substrate binding channel, but in a kinked (k) conformation to the β5i/β6 active site. The 2FO-FC electron density maps for the ligands bound to Thr1 of the chimeric β5 active sites are shown as blue meshes contoured at 1σ. The inhibitor and Thr1 have been omitted for phasing.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_5-B</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 5-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>B. Comparison of the conformations of ONX 0914, PR-924, 14, 16, 17 and 18 bound to the chimeric hβ5/hβ6 substrate binding channels. The l amino acid compounds ONX 0914 and 14 display a linear (l) binding mode to the hβ5c/hβ6 (left) and the hβ5i/hβ6 (right) chimeras, whereas the ligands 16 and 17 (P3-d-Ala and morpholine cap) adopt a kinked (k) conformation in both β5 substrate binding channels. Remarkably, the orientation of PR-924 and its analogue 18 (P3-d-Ala and 3-methyl-1H-indene cap) in the hβ5c/hβ6 chimera (and in WT yβ5; see Appendix Figure S5)) differs from that observed with the hβ5i/hβ6 chimera. Note that the inhibitors are rotated by about 45 ° compared to panel A.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:ONX</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="3" offset="38"/>
					
				
					<text>ONX</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:ONX</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="3" offset="161"/>
					
				
					<text>ONX</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_6-A</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 6-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>A. Complex structures of the mouse chimeric proteasome (left) and the hβ5i-V31M/hβ6 mutant (right) with PR-924 visualize the kinked (k) orientation. The 2FO-FC electron density maps for the ligands bound to Thr1 of the chimeric β5 active sites are depicted according to Fig 5A. Steric hindrance of Met31 (green) with the bulky 3-methyl-1H-indene cap is indicated by black double arrows.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:bulky</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="324"/>
					
				
					<text>bulky</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:V31M</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="4" offset="76"/>
					
				
					<text>V31M</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_6-B</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 6-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>B. Superposition of inhibitors bound to the mouse chimeric proteasome (left) and the hβ5i-V31M/hβ6 mutant (right). Compounds display the same binding modes (kinked (k) or linear (l)) to the mβ5i/mβ6 active site as to the corresponding human β5i/β6 subunit (Fig. 5) and to the hβ5i-V31M/hβ6 mutant. Note that the inhibitors are rotated by about 45° compared to panel A.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:V31M</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="4" offset="91"/>
					
				
					<text>V31M</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:V31M</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="4" offset="288"/>
					
				
					<text>V31M</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_6-C</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 6-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>C. Superposition of chimeric mammalian and WT yeast β5 active sites bound to the P3-d-Ala compounds PR-924 and 18. The nucleophilic Thr1 is depicted as well as the S1 pocket forming residues 31 and 45. Residue 31 impacts on the position of the 3-methyl-1H-indene cap of PR-924 and 18. Due to steric hindrance, the N-cap is shifted in the mouse and in the hβ5i-V31M/hβ6 chimera compared to the hβ5i/hβ6 mutant proteasome crystal structures (black double arrow). Note that the structures are rotated by 90° compared to panel B.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:V31M</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="4" offset="362"/>
					
				
					<text>V31M</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5283606 Figure_7-A</id>
			
		
			<infon key="sourcedata_document">2346</infon>
			
		
			<infon key="doi">10.15252/embj.201695222</infon>
			
		
			<infon key="pmc_id">5283606</infon>
			
		
			<infon key="figure">Figure 7-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_7-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>ONX 0914 binds in a linear mode to all active sites. Changing the stereochemistry at the P3 site from l-Ala (S) to d-Ala (R) leads to a kinked conformation in the β5 substrate binding channels (compound 16). Substitution of the morpholine cap of 16 by a larger 3-metyhl-1H-indene moiety yields PR-924 and results in different inhibitor conformations at the yβ5/hβ5c and the mammalian β5i active sites. Hereby, the selectivity for hβ5i over hβ5c is drastically increased (IC50 ratio hβ5c/hβ5i: 255) compared to ONX 0914 (IC50 ratio hβ5c/hβ5i: 20) and compound 16 (IC50 ratio hβ5c/hβ5i: 5.2, Fig 2). Residue Met31 of mβ5i sterically hinders the kinked binding mode of PR-924, thereby creating 7-fold selectivity for human β5i.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:sterically</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="10" offset="633"/>
					
				
					<text>sterically</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:Ala</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="3" offset="104"/>
					
				
					<text>Ala</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:Ala</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="3" offset="117"/>
					
				
					<text>Ala</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		

	</collection>
